<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biotech on IT News</title>
    <link>https://it-news.uk/tags/biotech/</link>
    <description>Recent content in Biotech on IT News</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 22 Jun 2026 00:00:00 +0800</lastBuildDate>
    <atom:link href="https://it-news.uk/tags/biotech/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>China Approves World&#39;s First CAR-T Therapy for Solid Tumors</title>
      <link>https://it-news.uk/posts/china-approves-world-first-car-t-solid-tumors/</link>
      <pubDate>Mon, 22 Jun 2026 00:00:00 +0800</pubDate>
      <guid>https://it-news.uk/posts/china-approves-world-first-car-t-solid-tumors/</guid>
      <description>&lt;p&gt;There&amp;rsquo;s a quiet but consequential shift happening in oncology — one that moves CAR-T therapy, until now largely confined to blood cancers, into the far larger arena of solid tumors. On June 22, China&amp;rsquo;s National Medical Products Administration (NMPA) approved satricabtagene autoleucel (brand name: Kailimei) through its priority review pathway, making it the first CAR-T product anywhere in the world to receive regulatory approval for a solid tumor indication.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
